Photo from academic.microsoft.com
G rowing attention has been focused on the benefits of sodium glucose cotransporter-2 (SGLT2) inhibitors, a novel class of oral hypoglycemic agents, in nephrology and diabetology. In Kidney International Reports,… Click to show full abstract
G rowing attention has been focused on the benefits of sodium glucose cotransporter-2 (SGLT2) inhibitors, a novel class of oral hypoglycemic agents, in nephrology and diabetology. In Kidney International Reports, Liu et al. reported an exploratory analysis of biomarkers affected by treatment with ertugliflozin, an SGLT2 inhibitor, using plasma samples from a proportion of participants in the VERTIS RENAL study, a multicenter, randomized, double-blind, placebo-controlled trial in which patients with type 2 diabetes and stage 3 chronic kidney disease were enrolled and followed up for 52 weeks. A total of 231 patients were available for this exploratory analysis, and they had a median age of more than 65 years, a median hemoglobin A1c level of 8.0%, a median urinary albumin-to-creatinine ratio of 29.5 mg/g, and a median
Journal Title: Kidney International Reports
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!